Compare Entegris Inc (ENTG) vs Mesoblast Limited (MESO) Price & Performance

ENTG trades at $162.19, down 2.48% today but maintains strong technical momentum with bullish moving averages and key support at $158. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.93 exceeding expectations by 13%. Revenue remains stable at $3.2B annually while net margins improved to 9.18% in 2026. Recent institutional buying from BlackRock and Baird Financial Group signals confidence in the semiconductor materials supplier.

ENTG presents a compelling growth story driven by AI semiconductor demand and operational improvements, with analyst consensus targeting 12.5% upside to $182.43. However, elevated valuation multiples (P/E 81.1, EV/EBITDA 31.7) and high long-term debt of $3.98B create vulnerability to sector downturns. The stock's performance hinges on continued execution amid semiconductor cycle volatility.

Mesoblast (MESO) trades at $13.75, down 1.36% with bearish technical signals despite recent FDA approval for its Ryoncil potency assay. The company shows significant revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent milestones include completing Phase 3 trials for chronic back pain treatment, positioning the biotech firm for potential market expansion in the $10 billion back pain market.

Investment outlook balances promising commercial progress against persistent financial losses. The stock offers speculative growth potential through FDA-approved therapies and pipeline developments, but carries substantial risk from ongoing cash burn and competitive pressures in the regenerative medicine space.